The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery.

Publication date: Jun 23, 2023

Differentiated service delivery and new products, such as long-acting injectable cabotegravir (CAB-LA) and the dapivirine vaginal ring (DVR), could increase uptake and use of pre-exposure prophylaxis (PrEP) for HIV prevention. We explored PrEP provider perspectives on differentiated PrEP service delivery and new PrEP products to inform World Health Organization (WHO) guidelines and programme implementation. 150 PrEP providers who participated in a WHO survey were randomly selected and 67 were invited for interviews based on geographic representation, provider cadre, gender, experience with community-based PrEP service delivery, and familiarity with new PrEP products. Semi-structured interviews were conducted virtually. Key themes were inductively extracted relating to differentiated service delivery and benefits and concerns regarding new PrEP products. 30 PrEP providers from 24 countries were interviewed. Across regions, providers were supportive of differentiated service delivery to respond to clients’ needs and preferences, maintain services during COVID-19, and ensure access for priority populations that may face access challenges. Providers welcomed prospects of offering CAB-LA to their clients but had concerns about HIV testing, costs, and the need for clinic-based services, including staff who can administer injections. Providers felt the DVR was potentially important for some cisgender women, especially young clients and female sex workers, and raised fewer concerns compared to injectable PrEP. Providers’ views are critical for the development of guidelines and implementing programmes that will best serve PrEP users. Understanding areas where provider capacities and biases may create barriers can define opportunities for training and support to ensure that providers can deliver effective programmes.

Open Access PDF

Concepts Keywords
Covid Health services
Future Healthcare providers
Interviews Pre-exposure prophylaxis


Type Source Name
drug DRUGBANK Cabotegravir
drug DRUGBANK Dapivirine
disease VO organization
disease MESH COVID-19
drug DRUGBANK Etoperidone
disease VO effective
disease MESH AIDS
drug DRUGBANK Tenofovir
disease MESH HIV infection
pathway REACTOME HIV Infection
disease IDO country
disease VO USA
disease MESH Hepatitis
disease MESH STIs
disease VO frequency
drug DRUGBANK Isoxaflutole
disease MESH Infections
disease VO device
drug DRUGBANK Trestolone
drug DRUGBANK Coenzyme M
disease VO protocol
drug DRUGBANK Serine
disease IDO facility
disease VO population
drug DRUGBANK Piroxicam
disease VO volume
disease VO monthly
disease MESH contraindications
disease MESH lifestyle
disease VO Hormone
disease VO time
disease MESH drug interactions
disease VO vaccination
disease VO injection
disease MESH uncertainty
disease MESH bacterial infections
disease IDO acute infection
drug DRUGBANK Adenosine
drug DRUGBANK Ademetionine
disease IDO intervention
disease MESH Opportunistic Infections
disease VO efficiency
drug DRUGBANK Dolutegravir
disease VO effectiveness
drug DRUGBANK L-Valine

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *